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Objectives: To evaluate the impact of adding a mobile health (mHealth) decision support system for antibiotic
prescribing to an established antimicrobial stewardship programme (ASP).
Methods: In August 2011, the antimicrobial prescribing policy was converted into a mobile application (app).
A segmented regression analysis of interrupted time series was used to assess the impact of the app on prescrib-
ing indicators, using data (2008–14) from a biannual point prevalence survey of medical and surgical wards.
There were six data points pre-implementation and six data points post-implementation.
Results: There was an increase in compliance with policy (e.g. compliance with empirical therapy or expert
advice) in the two specialties of medicine (6.48%, 95% CI"#1.25 to 14.20) and surgery (6.63%, 95%
CI"0.15–13.10) in the implementation period, with a significant sudden change in level in surgery (P,0.05).
There was an increase, though not significant, in medicine (15.20%, 95% CI"#17.81 to 48.22) and surgery
(35.97%, 95% CI"#3.72 to 75.66) in the percentage of prescriptions that had a stop/review date documented.
The documentation of indication decreased in both medicine (#16.25%, 95% CI"#42.52 to 10.01) and surgery
(#14.62%, 95% CI"#42.88 to 13.63).
Conclusions: Introducing the app into an existing ASP had a significant impact on the compliance with policy in
surgery, and a positive, but not significant, effect on documentation of stop/review date in both specialties. The
negative effect on the third indicator may reflect a high level of compliance pre-intervention, due to existing ASP
efforts. The broader value of providing an antimicrobial policy on a digital platform, e.g. the reach and access to
the policy, should be measured using indicators more sensitive to mHealth interventions.
Introduction
Technology in healthcare is constantly evolving. The application of
innovation and information technology has proliferated in every
aspect of healthcare delivery from using robotics to deliver non-
invasive surgical interventions, to electronic medical records, and
prescribing systems.1–3 With the advent of smartphones, and their
ubiquitous use by healthcare professionals, a new technological
platform has been introduced into healthcare. Increasingly, mobile
health (mHealth) is being used to deliver an array of different inter-
ventions through smartphone applications (apps) targeting both
healthcare professionals and healthcare users.4,5 In healthcare,
the development and implementation process of medical device
technologies is regulated, monitored or researched; however, for
information systems, e.g. electronic prescribing and smartphone
technology, there has to date been little regulation or govern-
ance.6 It is only in the last couple of years that the need for govern-
ance on the use of smartphone apps in healthcare has been
recognized.7
In the field of antimicrobial prescribing, where the drive to ad-
dress suboptimal antimicrobial prescribing in secondary care has
led to the development of many interventions, the use of clinical
prescribing tools and decision support systems has been well
documented.8–11 Such systems have been added to existing anti-
microbial stewardship programme (ASP) interventions in diverse
ways, ranging from pharmacy purchasing and ordering systems,
to electronic prescribing systems with specific add-ons targeting
antimicrobial prescribing, to providing access to susceptibility
data.12 Although they have shown some impact on tackling
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inappropriate antimicrobial prescribing in hospitals, data on the
long-term sustainable impact of such systems or their effect on
patient outcomes is lacking.8,13 It was to this plethora of electronic
interventions in healthcare, and in particular, in antimicrobial pre-
scribing, that mHealth technology was added. In the last 10 years
the number of healthcare-related smartphone apps has grown ex-
ponentially. In 2014 it was estimated that there were over 40 000
medical- and health-related apps available.14 In previous studies
we have reported on the frequent use of smartphone apps by
healthcare professionals during clinical consultations.15,16 In this
paper we report the effect of introducing a smartphone decision
support tool for antimicrobial prescribing on prescribing trends in
secondary care. This study builds on existing work we have con-
ducted in this field on the development of clinical decision support
systems to support antimicrobial prescribing.
Methods
Setting
This study was performed across the three main hospitals of Imperial
College Healthcare Trust (ICHT) Hospitals in west London. Across the sites
there are 1300 beds. At the time of the study the hospitals did not have any
electronic prescribing systems.
Ethics
Approval to conduct this study was obtained, via e-mail, by the ICHT and
Imperial College London joint research office (approval reference not ap-
plicable). All data used were anonymized, and all data were stored and
analysed in secure computers within the organization.
Intervention
The study extends over a 6 year period, 3 years pre-intervention and 3 years
post-intervention roll-out in August 2011. The hospitals already had a
multimodal ASP in place (Figure 1). In addition to this, the hospitals
are affiliated with an academic research unit dedicated to research in
antimicrobial stewardship. The Imperial antibiotic prescribing policy appli-
cation (IAPP) was developed as part of a collaboration and partnership be-
tween the academic and clinical staff across Imperial College. The IAPP
was launched across the hospitals in August 2011. The purpose of develop-
ing the app was to make the antimicrobial prescribing policy available at
the point of care. The IAPP was developed following a baseline study with
multi-professional stakeholder engagement investigating the prevalence
of the usage of smartphones amongst healthcare professionals.15,16
A multimodal dissemination strategy was used in the introduction and im-
plementation of the IAPP, with four communication channels: (i) teaching;
(ii) e-mails; (iii) the intranet homepage; and (iv) the ICHT newsletter.15 The
IAPP replaced a pocket guide that was no longer produced or disseminated.
Post-IAPP, the ASP already described continued. In 2012 the UK
Department of Health published the ‘Start Smart Then Focus’ guidance for
improving the quality of antimicrobial prescribing in hospitals.17 The key
elements of this guidance, which included steps for reviewing patients who
were prescribed therapeutic doses of antibiotics, were incorporated in the
updated version of the IAPP as pop-up prompts, launched in June 2012.
Between its launch in 2011 up to 2014, the IAPP underwent several iter-
ations, each time adding functionality in response to user feedback.
Point prevalence data
Data from the biannual point prevalence survey (PPS) that is conducted
across the hospitals were used for the interrupted time series (ITS) analysis
in this study. Clinical pharmacists use a standardized, protocol-driven data
collection form to collect the data from patient medication charts on wards.
All patients in hospital on the day of data collection are included in the
study. Data are collected from all patients receiving systemic antimicro-
bials. The key prescribing indicators the PPS measures are: (i) adherence of
choice of antimicrobial to local policy or microbiology/infectious disease
team recommendation; (ii) documentation of indication on medication
charts; and (iii) documentation of stop or review date on the medication
charts. These three indicators (choice, indication and stop or review date for
prescribed antimicrobials) were chosen as indicators to observe trends in
prescribing pre- and post-IAPP adoption. The impact of using mobile apps
on antibiotic prescribing outcomes has not been previously reported. In the
absence of direct outcome measures that can be linked to the effect of the
intervention, we used these existing, routinely collected data on antibiotic
At an organizational level the stewardship programme consisted of:
I. A consultant-led microbiology/infectious diseases team providing an advisory service
II. Multidisciplinary antimicrobial stewardship ward rounds
III. A team of dedicated antimicrobial stewardship pharmacists providing an advisory service
IV. An empirical policy available as a pocket guide and distributed to all junior doctors upon
employment, and as a link on the hospital intranet
V. Clinical pharmacists, part of whose responsibility was the clinical endorsement of all
prescriptions on the medication charts, visiting all wards on a daily basis
VI. A dedicated infection-control team consisting of infection-control nurses
VII. A multidisciplinary Antibiotic Review Group that met bimonthly ratified all policies and
guidelines related to antimicrobial use and treatment of infection
VIII. A project around awareness, education and feedback based on Plan, Do, Study, Act (PDSA)
methodology was initiated. The project was started in acute medicine (where the most
antibiotics were prescribed in the organization) and then rolled out to other disciplines.
Communication was unique to the discipline, i.e. we discussed with each the best way to
communicate. Some were e-mails with embedded results (no attachment), others were
paper copies on the ward, others were board meetings.19
Figure 1. Description of all the antimicrobial stewardship interventions in place during the time period of this study.
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prescribing outcomes as ‘proxy indicators’, or representative outcomes
measures of the impact of the IAPP.
Data from general medical and surgical patients were analysed separately
because at the time the IAPP was launched the ASP was more focused on
medicine. Within medicine, data from haematology, renal medicine and on-
cology were excluded from the analysis as these specialties were recognized
to have specialist policies separate from the empirical general policy for the
treatment of infections, and benefited from more targeted specialist input
from infectious disease and microbiology services. Data from ICUs were also
excluded from the analysis as antimicrobial therapy for patients in intensive
care is under daily review by infectious disease and medical microbiology staff.
Data analysis
A segmented regression analysis of ITS was used to evaluate the impact of
the IAPP. Six-monthly PPS data for the selected indicators from October
2008 to June 2014 were plotted. The clearly defined intervention period
(August 2011) and the availability of at least three data points before, and
three data points after the intervention enabled this quasi-experimental
design.18 The analysis estimated the intervention effect whilst taking ac-
count of time trend and autocorrelation among the observations. The ITS
allowed the estimation of any sudden change in level immediately after
the intervention, which is defined as the difference between the observed
level at the first intervention time point and that predicted by the pre-
intervention time trend, the estimation of the difference between pre- and
post-intervention slopes, and the estimation of the level effect 6, 12 and
24 months post-intervention. The level effect at 6, 12 and 24 months post-
implementation is the difference between the predicted value 6, 12 and
24 months post-intervention calculated with the pre-slope and the
observed value 6, 12 and 24 months post-implementation.8,19 After testing
the absence of first-order autocorrelations with the Durbin–Watson statis-
tic, a time series regression model, ARIMA (autoregressive integrated mov-
ing average), without adjustment for autocorrelation was fitted to the PPS
data. STATA version 12 (STATA Corp, College Station, TX, USA), statistical
software was used to perform the analysis.
Results
The timeline of the various interventions together with the
launch of the IAPP is plotted in Figure 2 along with the trends in
the three indicators measured in the biannual PPS (aggregated
data from medical and surgical specialties). There was a positive,
upwards trend for all the indicators prior to the launch of the
IAPP (Figure 3).
In the pre-implementation period, compliance with the policy
for the antibiotics prescribed was already high across both medi-
cine and surgery (Table 1 and Figure 3a and b). In the implementa-
tion period of the IAPP there was an increase in percentage
compliance with policy in both medicine (6.48%, 95% CI " –1.25
to 14.20) and surgery (6.63%, 95% CI"0.15–13.10), the change in
level was significant in surgery, but not in medicine (Table 1). The
level effect remained positive in both medicine and surgery at
6 and 12 months.
Documentation of a stop/review date had a lower baseline level
in the pre-intervention period (Figure 3c and d). In the implemen-
tation period, there was an increase in level in both medicine
(15.20%, 95% CI " #17.81 to 48.22) and surgery (35.97%, 95%
CI"#3.72 to 75.66) (Table 1). The change in slope pre- and post-
intervention as well as the level effect at 6, 12 and 24 months
post-IAPP were positive, but not significant.
Documentation of indication had significantly increased in
both medicine and surgery in the pre-implementation period. In
the post-implementation period, both slopes in medicine and sur-
gery changed significantly, resulting in a decrease in the docu-
mentation of the indication with a negative sudden change in
level of#16.25% (95% CI " #42.52 to 10.01) in medicine;
and#14.62% (95% CI"#42.88 to 13.63) in surgery. The change
in percentage of prescriptions with an indication remained
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Figure 2. Timeline of PPS data for the three indicators; the launch of the Department of Health’s ‘Start Smart Then Focus’ guidelines and the addition
of the surgical prophylaxis policy to the IAPP are indicated.
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negative but significant at 6, 12 and 24 months post-
implementation in both medicine and surgery.
Discussion
The introduction of the IAPP had a positive effect on compliance
with policy indicators in both medicine and surgery, as shown by
the sudden change in levels. In surgery the improvement was stat-
istically significant. The reasons for the observed effect in surgery
may be that most ASP interventions prior to the IAPP had focused
on medicine. As a result, this new intervention and decision sup-
port system may have had a greater effect in the surgical teams as
there were fewer other interventions that may have saturated the
effect. The baseline compliance with the empirical policy was high
Compliance with policy/approval by infection team medicine Compliance with policy/approval by infection team surgery
Documentation of a stop/review date medicine Documentation of a stop/review date surgery
Documentation of the indication medicine Documentation of the indication surgery
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in the study and this may be due to the existing and ongoing high-
level ASP activities across the organization. The IAPP improved
(shown by the sudden change in level) the documentation of the
stop/review date in both medical and surgical specialties, but this
improvement was not significant. The documentation of indication
had improved throughout the study, independent of the IAPP
intervention, and the introduction of the IAPP had a negative (but
not significant) effect, as shown by the sudden change in level.
One reason for this may be that, since early 2010, clinical pharma-
cists across the study hospital network were required to endorse
medication charts, and as part of the clinical responsibility to en-
sure judicious antimicrobial prescribing would document the indi-
cation onto the drug chart if the prescriber has not done so.
Using the PPS data as an indicator for antimicrobial prescribing
trends pre- and post-IAPP was possible because of the consistency
and the reliability of the PPS data. It also enabled the mapping of
other ASP interventions that were taking place across the organ-
ization. The three indicators have been collected consistently since
2008.
Identifying and isolating the appropriate outcome measure for
mHealth interventions in the context of an evolving and multifa-
ceted ASP is challenging. There is growing interest in the adoption
of mHealth in ASPs. Adoption of such interventions is an inevitable
progression of technology in healthcare. Any evaluation should be
done in the context of the added value that they will have to exist-
ing ASPs. Perhaps in organizations where the ASP is being newly
developed, the addition of smartphone apps may add significant
value. The cost-effectiveness of such interventions versus other
well-established components of ASP also requires further evidence
and evaluation. Staff may be more amenable to using mHealth to
gain access to booklets or pocket guides on local policies. The WHO
has recently published guidelines for reporting health interventions
using mobile phones.20 One of its key recommendations when de-
veloping mHealth interventions is the need to clarify what the
added value of such interventions is to existing systems. The IAPP
was introduced in 2011 at a time when using mHealth in health-
care was still a relatively new concept. The aim was to make the
local empirical antimicrobial prescribing policy more accessible to
staff and with the help of decision algorithms to encourage opti-
mized antimicrobial prescribing. Data on the roll-out and initial use
of IAPP have been published and the subsequent qualitative im-
pact of the app reported.15 However, developing a study that
measures the added effect of a clinical decision support system to
an existing multifaceted antimicrobial stewardship model across a
multi-site healthcare organization is more challenging. This may
be the case for any system where there is a saturation of interven-
tions targeting a single outcome, e.g. ASP. In the context of this
study electronic prescribing was not implemented at the time of
the implementation of the IAPP. It was precisely because of lack of
a uniform electronic prescribing system that the idea of a decision
support tool delivered through smartphone apps was considered
to be a possible way to provide point-of-care access to the existing
empirical policy.
The indicators used in this study were part of a larger and more
complex ASP in a real-life clinical setting. As such, establishing
causality between the implementation of the IAPP and the
observed trends in prescribing is not possible. The indicators
chosen did not measure the wide-ranging impact of the IAPP. The
mechanisms to measure and describe the utility of such mHealthTa
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interventions should be multimodal, and sensitive enough to
measure the added value in the context of multiple interventions
aimed at maximizing outcome measures. We would advocate
integrating quantitative measures such as those presented here
with qualitative criteria such as increased access to the policy at
the point of care, the reach of the policy to healthcare profes-
sionals and the feedback from users.15,21 In this study, the addition
of the antimicrobial prescribing policy as an mHealth app to a
multifaceted ASP did not demonstrate a significant change in anti-
microbial prescribing trends. The added value of the IAPP has been
in the reach and access to the antimicrobial prescribing policy
amongst a wider range of staff across our organization.15
Healthcare organizations aiming to implement apps as part of
ASPs should consider the evidence presented here in order to man-
age any expectations they might have of the impact of apps on
antimicrobial prescribing trends.
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